Literature DB >> 8017863

Two independent amplification events on chromosome 7 in glioma: amplification of the epidermal growth factor receptor gene and amplification of the oncogene MET.

B Wullich1, H P Sattler, U Fischer, E Meese.   

Abstract

Amplifications of cellular oncogenes and growth factor genes have previously been reported in gliomas. Here we have evaluated 21 gliomas for amplification of tumor related genes including NMYC, EGFR, TGFalpha, MET, CMYC, SRC, HRAS, NRAS, SEC, ROS1, JUN, and WNT1. Five amplifications were observed. The epidermal growth factor receptor (EGFR) gene was amplified in 4 glioblastomas. The oncogene MET was amplified in a glioblastoma which showed no EGFR gene amplification. Importantly, both genes are located on chromosome 7 and belong to a family with tyrosine kinase activity. There was no amplification found for TGFalpha which was previously reported to be amplified in gliomas. The finding of MET and EGFR independently amplified in glioma lends further support to a crucial role of chromosome 7 in the development of gliomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8017863

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases.

Authors:  M Udart; J Utikal; G M Krähn; R U Peter
Journal:  Neoplasia       Date:  2001 May-Jun       Impact factor: 5.715

2.  Genetic profile of gliosarcomas.

Authors:  R M Reis; D Könü-Lebleblicioglu; J M Lopes; P Kleihues; H Ohgaki
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

3.  Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; M Hamza Müslümanoglu; Muhsin Ozdemir; Ramazan Durmaz; Didem Arslantas; Murat Vural; Erhan Cosan; Metin Ant Atasoy
Journal:  Pathol Oncol Res       Date:  2007-03-27       Impact factor: 3.201

4.  Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription.

Authors:  Kevin A Walter; Mir Ahamed Hossain; Carey Luddy; Nidhi Goel; Thomas E Reznik; John Laterra
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

5.  Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens.

Authors:  Sanja Ivkovic; Christopher Beadle; Sonal Noticewala; Susan C Massey; Kristin R Swanson; Laura N Toro; Anne R Bresnick; Peter Canoll; Steven S Rosenfeld
Journal:  Mol Biol Cell       Date:  2012-01-04       Impact factor: 4.138

Review 6.  Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.

Authors:  Nichola Cruickshanks; Ying Zhang; Fang Yuan; Mary Pahuski; Myron Gibert; Roger Abounader
Journal:  Cancers (Basel)       Date:  2017-07-11       Impact factor: 6.639

7.  The role of myosin II in glioma invasion: A mathematical model.

Authors:  Wanho Lee; Sookkyung Lim; Yangjin Kim
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240

8.  Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer.

Authors:  Shinya Akatsuka; Yoriko Yamashita; Hiroki Ohara; Yu-Ting Liu; Masashi Izumiya; Koichiro Abe; Masako Ochiai; Li Jiang; Hirotaka Nagai; Yasumasa Okazaki; Hideki Murakami; Yoshitaka Sekido; Eri Arai; Yae Kanai; Okio Hino; Takashi Takahashi; Hitoshi Nakagama; Shinya Toyokuni
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

9.  High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer.

Authors:  F Zagouri; Z Bago-Horvath; F Rössler; A Brandstetter; R Bartsch; C A Papadimitriou; C Dimitrakakis; A Tsigginou; I Papaspyrou; A Giannos; M-A Dimopoulos; M Filipits
Journal:  Br J Cancer       Date:  2013-02-19       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.